Nectintx is a groundbreaking biotech company dedicated to revolutionizing the lives of cancer patients. With a focus on pioneering the development of next-generation immune oncology (IO) therapies, we aim to set new standards for efficacy and patient response rates across difficult-to-treat cancers. Our cutting-edge technology tackles major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies (mAbs) and antibody-drug-conjugates (ADCs).

Established in 2017 and backed by renowned partners such as aMoon Fund, Peregrine Ventures, and Integra Holdings, Nectintx is led by a team of experts with extensive experience in oncology research and development. Our innovative therapies, including NTX1088 and NTX2R13, have demonstrated superior tumor regression and synergize with approved PD(L)1 blockers. This raises the exciting possibility of developing combination immunotherapies.

We are also engaged in the development of a pipeline of first-in-class and best-in-class ADC therapies, leveraging our technological platform. These therapies have shown robust tumor regression in multiple in vivo models of both solid and hematological malignancies. To connect with us or learn more, please visit our offices in Jerusalem, Israel, or Fort Lee, New Jersey, USA.

Copyright ©2022 Nectintx. All Rights Reserved